Vanda

FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date

ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda's r...

Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders

... ROCKVILLE, Md., May 29 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced t...y vote at the meeting or any adjournment thereof. vanda anticipates mailing its proxy statement in July 20...ption of the matters to be considered. About vanda ...

Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital

... ROCKVILLE, Md., May 7 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) ("Vanda" or...s for the election of two of its candidates to the vanda Board at the Company's 2009 Annual Meeting and for...g director of the general partner of TCP, notified vanda of TCP's intention not to pursue a proxy contest o...

Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP

...OCKVILLE, Md., Feb. 23 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) ("Vanda" or... following statement regarding two letters sent to vanda by Tang Capital Partners, LP ("TCP") and a SEC fil... bylaws and request that the Board of Directors of vanda take action to liquidate the Company. In acco...

New medication brings hope of jet lag cure

... A team of researchers from Monash University, The Brigham and Women's Hospital (Boston), Harvard Medical School and vanda Pharmaceuticals has found a new drug with the potential to alleviate jet lag and sleep disorders caused by shift work. Dr Shantha Rajaratnam from ...

Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone

... ROCKVILLE, Md., July 28 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced to... treatment of schizophrenia. The FDA stated that vanda had demonstrated the effectiveness of iloperidone ...further. The FDA also stated that it would require vanda to obtain additional safety data for patients at a...

Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference

... ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharma...day announced that Mihael H. Polymeropoulos, M.D., vanda President and CEO will deliver a corporate present...ior to the start of the live presentation. About vanda Pharmaceuticals Inc. ...

Stater Bros. Raises $501,707 for American Heart Association

...fund-raising stores and the Top 10 fund-raising Stater Bros. Clerks were honored for their outstanding efforts. Also in attendance was college student vanda Mittal who suffered a massive stroke three years ago at the age of 15. She is now leading a full life and looks forward to helping others with deficit...

Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes

... ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced that, despite strong demand...hat involve risks, changes in circumstances, assumptions and uncertainties. vanda is at an early stage of development and may not ever have any products that...

Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties

... ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharma...nism to address disorders of excessive sleepiness. vanda plans to conduct additional studies to further und...r, as well as neurodegenerative disorders." About vanda Pharmaceuticals Inc. ...

Vanda in Medical Technology

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt(TM) (iloperidone) for the acute treatment of adult patients with schizophrenia. The approval was supp...

Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) reports publication in The Lancet , one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162). The publication...

Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia

Study Meets Primary Endpoint, with Positive Effect Sustained Through Duration of 4-Week Study ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) (Vanda) today announced positive top-line results from a Phase III trial showing ...

Vanda Pharmaceuticals Provides Update on Iloperidone

...tter that the company received on July 25, 2008. vanda presented arguments to support its belief that ilo... a useful agent for patients with schizophrenia. vanda has now agreed to provide a complete response to t... any FDA review is uncertain at this time. ABOUT vanda PHARMACEUTICALS INC.: ...

Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events

...at may help predict response to iloperidone, which vanda believes could lead to unique, individualized trea...Paolo Baroldi, M.D., Ph.D., Chief Medical Officer, vanda Pharmaceuticals Inc. About vanda Pharmaceuticals Inc. ...

Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)

...o antipsychotic treatment. The study, conducted by vanda Pharmaceuticals Inc., included patients with acute...ry Research, The Zucker Hillside Hospital. About vanda Pharmaceuticals Inc. vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) is a biophar...

Vanda Presents Phase III Iloperidone Efficacy Data

... ROCKVILLE, Md., Dec. 12 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced to...Administration (FDA) accepted the NDA submitted by vanda for marketing approval on November 26, 2007. The Phase III study conducted by vanda evaluated the efficacy of iloperidone versus place...

Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application

... ROCKVILLE, Md., Nov. 27 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced to...fficient efficacy and tolerability issues. About vanda Pharmaceuticals Inc. vanda Pharmaceuticals Inc. is a biopharmaceutical compan...

Vanda Pharmaceuticals Reports Third Quarter 2007 Results

... ROCKVILLE, Md., Nov. 8 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharma...s for the third quarter ended September 30, 2007. vanda reported research and development (R&D) expenses i...NAL HIGHLIGHTS Iloperidone On September 27, 2007 vanda announced that it had submitted an NDA to the U.S....

Vanda Pharmaceuticals Submits Iloperidone New Drug Application

...Mihael H. Polymeropoulos, M.D., President and CEO, vanda Pharmaceuticals Inc. "For a serious brain disorde...ufficient efficacy and tolerability issues. About vanda Pharmaceuticals Inc. vanda Pharmaceuticals Inc. is a biopharmaceutical compan...

Vanda in Biological Technology

LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests

BURLINGTON, N.C. and ROCKVILLE, M.D., June 5 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH ), one of the world's leading clinical trials and genetic testing laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharmaceutical comp...

Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009

... ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ), a ...tly before the 10:00 AM start time and ask for the vanda Pharmaceuticals conference call hosted by Dr. Poly...ers. The access number is 78449791. ABOUT vanda PHARMACEUTICALS INC.: ...

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

... ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced t...r the acute treatment of schizophrenia in adults. vanda will also present two posters on tasimelteon at AP...nce Model of Transient Insomnia. About vanda ...

Vanda Pharmaceuticals Reports First Quarter 2009 Results

...ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharm...for the first quarter ended March 31, 2009. vanda reported a net loss of $6.5 million for the first ...9, a total of approximately 26.7 million shares of vanda common stock were outstanding. Net loss per common...

New Insights into the Mechanism of Action of Antipsychotic Drugs

...ROCKVILLE, Md., March 10 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) reports the...tics that sheds new light on how these drugs work. vanda researchers analyzed the mechanism of action of 18...phr Res. 2009 Mar; 108(1-3):134-42. About vanda Pharmaceuticals Inc.: ...

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results

... ROCKVILLE, Md., Feb. 11 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharm...the fourth quarter ended December 31, 2008. vanda reported a net loss of $7.5 million for the fourth...8, a total of approximately 26.7 million shares of vanda common stock were outstanding. Net loss per common...

Vanda Pharmaceuticals Reports Third Quarter 2008 Results

... ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharma... for the third quarter ended September 30, 2008. vanda reported research and development (R&D) expenses i... chronic primary insomnia clinical trial for which vanda announced top-line results in June of 2008. The de...

Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights

...rs, announced today that the Board of Directors of vanda Pharmaceuticals Inc. (the "Company") declared a di...stribution is not taxable to stockholders. ABOUT vanda PHARMACEUTICALS INC.: vanda Pharmaceuticals Inc. is a biopharmaceutical compan...

Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008

... ROCKVILLE, Md., July 31 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharma...al callers. The access number is 98529573. About vanda Pharmaceuticals Inc.: vanda Pharmaceuticals Inc. is a biopharmaceutical compan...

Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference

... ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- vanda Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharma...da. The presentation will be available live on the vanda Website, where it also will be archived for 30 day...rior to the start of the live presentation About vanda Pharmaceuticals Inc. ...